Mokhoa o Mocha oa 2019 3-Aminopyrazine-2-Carboxylic Acid CAS No. 5424-01-1

Liphihlelo tse ngata haholo tsa tsamaiso ea merero le mofuta o le mong ho ea ho o mong oa mofani oa litšebeletso li etsa bohlokoa bo boholo ba puisano ea mokhatlo le kutloisiso ea rona e bonolo ea litebello tsa hau bakeng sa 2019 New Style 3-Aminopyrazine-2-Carboxylic Acid CAS No. 5424-01-1, We ba ikemiselitse ho u fa theko e tlase ka ho fetisisa 'marakeng, boleng bo holimo le tšebeletso e ntle haholo ea thekiso.Rea u amohela ho etsa bussines le rona, ha re beng ka makhetlo a mabeli.
Liphihlelo tse ngata haholo tsa tsamaiso ea merero le mofuta o le mong ho mofani a le mong li etsa bohlokoa bo boholo ba puisano ea mokhatlo le kutloisiso ea rona ea litebello tsa hau bakeng saChina 3-Aminopyrazine-2-Carboxylic Acid le 5424-01-1, Thepa ea rona e tumme haholo ka lentsoe, joalo ka Amerika Boroa, Afrika, Asia joalo-joalo.Likhamphani ho "etsa lihlahisoa tsa boemo ba pele" e le sepheo, 'me li ikitlaelletsa ho fa bareki litharollo tsa boleng bo holimo, ho fana ka litšebeletso tsa boleng bo holimo ka mor'a thekiso le tšehetso ea tekheniki, le ho thusa bareki, ho theha mosebetsi o motle le bokamoso!

2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid e sebelisoa e le bohareng ba Eltrombopag.
Eltrombopag, e ntlafalitsoeng ke GlaxoSmithKline (GSK) naheng ea UK, 'me hamorao e ile ea ntlafatsoa ka kopanelo le Novartis naheng ea Switzerland, ke molek'hule oa pele o amohetsoeng oa molek'hule o se nang peptide TPO receptor agonist lefatšeng.Eltrombopag e amohetsoe ke US FDA ka 2008 bakeng sa kalafo ea idiopathic thrombocytopenic purpura (ITP), le ka 2014 bakeng sa kalafo ea anemia e matla ea aplastic (AA).Hape ke moriana oa pele o amohetsoeng ke US FDA bakeng sa kalafo ea AA lilemong tse 30 tsa morao tjena.
Ka December 2012, US FDA e ile ea amohela Eltrombopag bakeng sa phekolo ea thrombocytopenia ho bakuli ba nang le lefu la sebete le sa foleng la C (CHC), e le hore bakuli ba hepatitis C ba nang le bokooa bo bobe ka lebaka la palo e tlaase ea platelet ba ka qala le ho boloka phekolo e tloaelehileng ea interferon bakeng sa mafu a sebete.Ka February 3, 2014, GlaxoSmithKline e phatlalalitse hore FDA e fane ka katleho ea meriana ea phekolo ea Eltrombopag bakeng sa phekolo ea hemopenia ho bakuli ba nang le lik'hemik'hale tse matla tsa aplastic anemia (SAA) tse sa kang tsa arabela ka botlalo ho immunotherapy.Ka August 24, 2015, US FDA e amohetse Eltrombopag bakeng sa phekolo ea thrombocytopenia ho batho ba baholo le bana ba lilemo li 1 ho ea holimo ba nang le lefu le sa foleng la immune thrombocytopenia (ITP) ba nang le karabelo e sa lekaneng ho corticosteroids, immunoglobulins kapa splenectomy.Ka January4, 2018, Eltrombopag e ile ea amoheloa hore e ngolisoe Chaena bakeng sa phekolo ea "immune immune thrombocytopenia" (ITP).

Liphihlelo tse ngata haholo tsa tsamaiso ea merero le mofuta o le mong ho ea ho o mong oa mofani oa litšebeletso li etsa bohlokoa bo boholo ba puisano ea mokhatlo le kutloisiso ea rona e bonolo ea litebello tsa hau bakeng sa 2019 New Style 3-Aminopyrazine-2-Carboxylic Acid CAS No. 5424-01-1, We ba ikemiselitse ho u fa theko e tlase ka ho fetisisa 'marakeng, boleng bo holimo le tšebeletso e ntle haholo ea thekiso.Rea u amohela ho etsa bussines le rona, ha re beng ka makhetlo a mabeli.
Setaele se Secha sa 2019China 3-Aminopyrazine-2-Carboxylic Acid le 5424-01-1, Thepa ea rona e tumme haholo ka lentsoe, joalo ka Amerika Boroa, Afrika, Asia joalo-joalo.Likhamphani ho "etsa lihlahisoa tsa boemo ba pele" e le sepheo, 'me li ikitlaelletsa ho fa bareki litharollo tsa boleng bo holimo, ho fana ka litšebeletso tsa boleng bo holimo ka mor'a thekiso le tšehetso ea tekheniki, le ho thusa bareki, ho theha mosebetsi o motle le bokamoso!